Evidence map›Paper›PMID 35614440›Full record

ArticleHarm reduction journal2022

Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada.

Mana Moshkforoush, Kora DeBeck, Rupinder Brar, Nadia Fairbairn, Zishan Cui, M-J Milloy, Jane Buxton, Tanis Oldenburger, Will McLellan, Perry Kendall and 4 more

Open access · goldAbstract read
In one paragraph

Article in Harm reduction journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Mana MoshkforoushBC Centre on Substance Use, Vancouver, Canada.
Kora DeBeckSchool of Public Policy, Simon Fraser University, Burnaby, Canada.
Rupinder BrarRegional Addiction Program, Vancouver Coastal Health, Vancouver, Canada.
Nadia FairbairnDepartment of Medicine, University of British Columbia, Vancouver, Canada.
Zishan CuiBC Centre on Substance Use, Vancouver, Canada.
M-J MilloyDepartment of Medicine, University of British Columbia, Vancouver, Canada.
Jane BuxtonBC Centre for Disease Control, Vancouver, Canada.
Tanis OldenburgerBC Centre on Substance Use, Vancouver, Canada.
Will McLellanMountainside Harm Reduction Society, Chilliwack, Canada.
Perry KendallDepartment of Medicine, University of British Columbia, Vancouver, Canada.
Kali SedgemoreBC Centre on Substance Use, Vancouver, Canada.
Dean WilsonBC Centre on Substance Use, Vancouver, Canada.
Thomas KerrDepartment of Medicine, University of British Columbia, Vancouver, Canada.
Kanna HayashiBC Centre on Substance Use, Vancouver, Canada. bccsu-kh@bccsu.ubc.ca.
British Columbia Centre on Substance Use · CAUniversity of British Columbia · CASimon Fraser University · CABC Centre for Disease Control · CAVancouver Coastal Health · CA

Funding

Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDSU01DA038886 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI DEBECK, KORA, HAYASHI, KANNA · 2015 to 2024
$12.1M
Impacts of universal access to HIV/AIDS care among HIV+ injection drug usersU01DA021525 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MILLOY, M-J · 2017 to 2024
$4.3M
CIHR MS1-173065NIDA NIH HHS U01 DA021525NIDA NIH HHS U01 DA038886US National Institutes of Health U01DA021525US National Institutes of Health U01DA038886
6 · The paper itself

Abstract

backgroundWhen the novel coronavirus pandemic emerged in March 2020, many settings across Canada and the USA were already contending with an existing crisis of drug overdoses due to the toxic unregulated drug supply. In response, the Canadian province of British Columbia (BC) released innovative risk mitigation prescribing (RMP) guidelines for medical professionals to prescribe pharmaceutical alternatives to unregulated drugs in an effort to support the self-isolation of people who use unregulated drugs (PWUD) in preventing both SARS-CoV-2 virus infection and overdoses. We sought to assess the level of awareness of RMP and identify factors associated with this awareness among PWUD in Vancouver, BC.

methodsCross-sectional data were derived from participants enrolled in three community-recruited prospective cohort studies of PWUD in Vancouver, interviewed between July and November 2020. Multivariable logistic regression analysis was used to identify factors associated with awareness of RMP.

resultsAmong 633 participants, 302 (47.7%) had heard of RMP. Of those 302 participants, 199 (65.9%) had never tried to access RMP services, ten (3.3%) made an unsuccessful attempt to access RMP, and 93 (30.8%) received RMP. In the multivariable analysis, participants who had awareness of RMP guidelines were more likely to self-identify as white (adjusted odds ratio [AOR] = 1.47; 95% confidence interval [CI]: 1.01, 2.13), to have completed secondary school education or higher (AOR = 1.67; 95% CI: 1.16, 2.39), to have used drugs at a supervised consumption or overdose prevention site in the past six months (AOR = 1.66; 95% CI: 1.10, 2.52), and to have received opioid agonist therapy as treatment for opioid use disorder in the past six months (AOR = 1.51; 95% CI: 1.02, 2.24).

conclusionAt least four months after the release of the guidelines, RMP was known to less than half of our study participants, warranting urgent educational efforts for PWUD, particularly among racialized groups and those who were not accessing other harm reduction services. Furthermore, the majority of participants who were aware of RMP guidelines had never tried to access the service, suggesting the need to improve perceived accessibility and knowledge of eligibility criteria.

Indexed as

COVID-19Drug OverdoseBritish ColumbiaCanadaCross-Sectional StudiesHumansProspective StudiesSARS-CoV-2COVID-19Drug overdoseHarm reductionSafe supply

Identifiers

PMID35614440
PMCPMC9131310
OpenAlexW4281487826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.